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Vitamin D Status and Depressive
Symptoms in Older Adults: A Role for
Physical Functioning?
Elisa J. de Koning, M.Sc., Liset E.M. Elstgeest, M.Sc., Hannie C. Comijs, Ph.D.,
Paul Lips, M.D., Ph.D., Judith J.M. Rijnhart, M.Sc., Harm W.J. van Marwijk, M.D., Ph.D.,
Aartjan T.F. Beekman, M.D., Ph.D., Marjolein Visser, Ph.D.,
Brenda W.J.H. Penninx, Ph.D., Natasja M. van Schoor, Ph.D.
Objectives: Depressive symptoms and low vitamin D status are common in older persons
and may be associated, but findings are inconsistent.This study investigated whether
25-hydroxyvitamin D (25(OH)D) concentrations are associated with depressive symp-
toms in older adults, both cross-sectionally and longitudinally.We also examined whether
physical functioning could explain this relationship, to gain a better understanding
of the underlying mechanisms. Methods: Data from two independent prospective cohorts
of the Longitudinal Aging Study Amsterdam were used: an older cohort (≥65 years,
n = 1282, assessed from 1995–2002) and a younger-old cohort (55–65 years, n = 737,
assessed from 2002–2009). Measurements: Depressive symptoms were measured at
baseline and after 3 and 6 years with the Center of Epidemiological Studies Depres-
sion Scale. Cross-sectional and longitudinal linear regression techniques were used
to examine the relationship between 25(OH)D and depressive symptoms. The medi-
ating role of physical functioning was examined in the longitudinal models. Results:
Cross-sectionally, associations were not significant after adjustment for confounders.
Longitudinally, women in the older cohort with baseline 25(OH)D concentrations up
to 75 nmol/L experienced 175 to 24% more depressive symptoms in the following 6
years, compared with women with 25(OH)D concentrations >75 nmol/L.Reduced phys-
ical performance partially mediated this relationship. In men and in the younger-old
cohort, no significant associations were observed. Conclusions: Older women showed
an inverse relationship between 25(OH)D and depressive symptoms over time, which
may partially be explained by declining physical functioning.Replication of these find-
ings by future studies is needed. (Am J Geriatr Psychiatry 2018; 26:1131–1143)
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Article Highlights
• This study examined the association between vitamin D status and depressive symptoms.
• Physical functioning was explored as a possible mediator in this relationship.
• Two large cohorts of older persons were analyzed cross-sectionally and longitudinally.
• Older women with low vitamin D status reported more depressive symptoms over
time.
• Decreased physical functioning may partially explain this association.
Worldwide, depression is a leading cause of dis-ability, resulting in significant individual and
societal burden.1 In addition, low 25-hydroxyvitamin
D (25(OH)D) concentrations are common, especially
among older persons.2,3 Meta-analyses have shown an
inverse association between 25(OH)D concentrations
and depressive symptoms, but findings are inconsis-
tent and longitudinal studies are scarce.4,5
A large Italian population-based cohort of older adults
found that persons with low baseline 25(OH)D had more
depressive symptoms after 3 and 6 years compared with
persons with higher baseline 25(OH)D.6 Chan et al. found
an inverse cross-sectional, but no prospective, associ-
ation between 25(OH)D and depressive symptoms in
older persons,7 whereas Williams et al. observed the op-
posite pattern.8 Furthermore, older adults with low
25(OH)D had an almost threefold risk of major depres-
sive disorder (MDD) after one year compared with
persons with normal 25(OH)D concentrations, in a pop-
ulation with cardiovascular disease.9
Biologically, a link between vitamin D status and de-
pressive symptoms is plausible, through protective
functions of vitamin D metabolites in the brain10–12 and
the presence of the vitamin D receptor in depression-
related brain areas such as the hippocampus.13 To better
understand the mechanisms underlying the pre-
sumed association between 25(OH)D and depression,
a mediating role of physical functioning in this rela-
tionship can also be considered. Physical functioning
is associated with both 25(OH)D and depression: Low
25(OH)D concentrations were associated with lower
and declining physical performance,14,15 and bidirec-
tional cross-sectional and prospective relationships
between physical functioning and depression have been
observed.16–20
The present cohort study investigated whether
25(OH)D concentrations are associated with the se-
verity (cross-sectionally) and the course and onset
(longitudinally) of depressive symptoms in older adults.
In secondary analyses, this study investigated whether
physical functioning explains the association between
25(OH)D and depressive symptoms. Data from two in-
dependent cohorts of the Longitudinal Aging Study
Amsterdam (LASA) were used.21 Part of this data set
was also used in a cross-sectional study by Hoogendijk
et al.,2 on which the present study elaborates.
Hoogendijk et al. observed that depressive symp-
toms (as determinant) were associated with lower
25(OH)D in one LASA cohort. The present study ad-
ditionally investigated a second LASA cohort and
examined longitudinal associations. By studying two
independent cohorts, we aimed to provide more insight
into the relationship between 25(OH)D and depres-
sive symptoms across a wide age range.
METHODS
Design and Study Sample
LASA is an ongoing population-based prospective
cohort study that investigates the predictors, conse-
quences, and time course of physical, cognitive,
emotional, and social functioning in multiple cohorts
of older adults.21 Participants were recruited from mu-
nicipality registries in three regions in the Netherlands,
together constituting a representative sample of the
Dutch older population. Every 3 years, LASA partici-
pants are invited for interviews and questionnaires.
Interviews are conducted at the participants’ homes by
trained interviewers.
Data from two LASA cohorts were used. In 1992,
3,107 participants aged 55 to 85 years were included
in the first LASA cohort (“older cohort”). As 25(OH)D
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was first assessed in 1995–1996, we took this second
measurement cycle as baseline for this cohort. Partici-
pants of 65 years and older who agreed to have an
additional medical interview (n = 1,509) were asked to
donate a blood sample. Serum 25(OH)D levels were
available from 1,320 participants.
The second LASA cohort commenced in 2002–
2003 with 1,002 participants aged 55 to 65 years
(“younger-old cohort”). Of the 919 participants who
agreed to the medical interview, 739 participants had
data on 25(OH)D.
Follow-up time for the present study was 6 years.
Follow-up data were collected at the subsequent two
measurement cycles: in 1998–1999 and 2001–2002 (older
cohort), and in 2005–2006 and 2008–2–09 (younger-
old cohort).
All participants gave written informed consent prior
to the start of the study. The LASA study was ap-
proved by the medical ethics committee of the VU
University Medical Center. Detailed information about
LASA and its participants can be found elsewhere.21
Measurements
Depressive Symptoms
The Center for Epidemiological Studies Depression
Scale (CES-D)22 was assessed at baseline and 3 and 6
years in both cohorts. The CES-D is a widely used
screening instrument that contains 20 items about de-
pressive symptoms as experienced in the previous week.
Scores range from 0 to 60, with higher scores indicat-
ing more depressive symptoms. A score of 16 or more
is indicative for clinically relevant depressive symp-
toms. The CES-D displays high reliability23 and good
criterion validity24 in several older populations.
Blood Sampling and Measurement of 25(OH)D
Morning blood samples for the assessment of serum
25(OH)D (in nmol/L) were obtained in 1995–1996
(older cohort) and 2002–2003 (younger-old cohort). Par-
ticipants were allowed to have a light breakfast without
dairy products. Samples were centrifuged and stored
at −20°C until 25(OH)D determination in 1997–1998
(older cohort) and 2010–2011 (younger-old cohort). The
analyses were carried out by the VU University Medical
Center Endocrine Laboratory. A competitive protein-
binding assay (Nichols Diagnostics, Capistrano, CA;
interassay coefficient of variation [CV]: 10%) was used
for the sample determinations in the older cohort,
whereas a radioimmunoassay (Diasorin, Stillwater, MN;
interassay CV: 10%) was used for the younger-old
cohort. For the statistical analyses of the present study,
25(OH)D was divided into four categories using com-
monly used cutoff values: less than 30 nmol/L
(deficiency), 30 to 50 nmol/L (insufficiency), 50 to
75 nmol/L, and greater than 75 nmol/L.25,26
Potential Effect Modifier and Confounders
Sex was examined as a potential effect modifier, as
previous studies observed different associations
between 25(OH)D and depressive symptoms in men
and women.6,9 Education level (years), smoking habits
(never, former, current smoker), alcohol consump-
tion (grams/week, 10 g per consumption), presence of
the most prevalent somatic chronic diseases among
Dutch older adults (asthma/chronic obstructive pul-
monary disease, cardiac disease [myocardial infarction,
coronary artery disease, heart failure, disease of the
cardiac valves, arrhythmia], peripheral arterial disease,
diabetes mellitus, cerebrovascular accident/stroke,
osteoarthritis/rheumatoid arthritis, cancer, hyperten-
sion, and other diseases that are present for at least 3
months) and general cognitive functioning (Mini-
Mental State Examination)27 were obtained during the
interviews and questionnaires. To control for season-
al variations in 25(OH)D concentrations,28 the blood
collection dates were dichotomized into winter
(October–March) and summer (April–September). Body
mass index was calculated by dividing measured body
weight (in kilograms) by measured body height (in
meters) squared. Information on physical activity in
the previous 2 weeks (walking, cycling, sports, heavy
household activities, in minutes/day, plus the ques-
tion whether these activities were representative
compared to the previous year) was taken from the
LASA Physical Activity Questionnaire (LAPAQ).29
Potential Mediating Variables
To cover a broad domain of physical functioning,
both objective performance tests and self-reported func-
tional limitations were examined for their possible
mediating role in the association between 25(OH)D and
depressive symptoms. A modified version of the Short
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Physical Performance Battery (SPPB)15,30 was used to
assess physical performance. The SPPB includes three
tests: walking speed (walking 3 meters, turning around
and walking back 3 meters as fast as possible), chair
stands (standing up from a chair without using hands
five times consecutively, as fast as possible) and stand-
ing balance (standing with one foot directly in front
of the other for up to 10 seconds). In the older cohort,
the total score of the SPPB ranged from 0 to 12. As the
balance test was not administered to the younger-old
cohort at baseline, the SPPB score for this cohort was
composed of the walking speed and chair stands scores
only, resulting in a score range of 0 to 8. Higher scores
indicate better physical performance.
Functional limitations were measured with six ques-
tions assessing common daily activities: climbing stairs,
cutting toenails, walking 5 minutes without resting,
rising from a chair, (un)dressing, and using own/
public transportation.31 The participants indicated
whether they had difficulty performing these activi-
ties (score range: 0–6). Higher scores indicate more
functional limitations.
Statistical Analyses
As the two cohorts differed in age range, assess-
ment period, and 25(OH)D assay, analyses were
conducted separately for both cohorts. All analyses were
conducted with SPSS version 22 (SPSS Inc., Chicago,
IL), except for the mediation analyses, which were con-
ducted with Mplus (version 7.2) and R statistical
software (version 3.2.5). A double-sided p value of less
than 0.05 was considered statistically significant. Base-
line descriptive statistics were calculated and presented
as n / % for categorical variables or as median /
interquartile range for skewed continuous variables.
Cross-sectional and longitudinal non-response analy-
ses comparing included and excluded participants were
conducted with Pearson χ2 tests for categorical vari-
ables or with non-parametric Mann-Whitney tests for
skewed continuous variables.
As the distribution of the CES-D scores was skewed
to the right, these scores were log-transformed using the
formula ln(1 + CES-D score). The four 25(OH)D catego-
ries were entered as three dummy variables in the
regression analyses, with the >75 nmol/L group as ref-
erence category. To test the association of 25(OH)D with
depressive symptoms, we first looked at the overall,
three degrees of freedom (df) tests of the 25(OH)D
dummies. If this test was statistically significant, we sub-
sequently looked at the associations of the separate
dummy variables with depressive symptoms. The Bs,
standard errors (SEs), and confidence intervals (CIs) of
the regression analyses were transformed back to obtain
interpretable ratios (eB = ratio). These ratios reflect the
percentage of change in the outcome per one unit change
in the determinant. As these ratios and resulting per-
centages were calculated from a log-transformed scale,
note that they do not correspond to the same change
in CES-D across all CES-D scores: higher scores change
more than lower scores. For instance, with a ratio of 1.23
and corresponding percentage change of 23%, a CES-D
score of 20 changes 4.6 points (23% of 20), whereas a
CES-D score of 10 changes 2.3 points (23% of 10).
Cross-Sectional Analyses
Multiple linear regression analyses with the 25(OH)D
categories as determinants and the CES-D score as
outcome were conducted. To assess effect modifica-
tion, sex and interaction terms of the 25(OH)D
categories with sex (25(OH)D dummies × gender) were
added to the unadjusted model. If an interaction term
had a p value of less than 0.05, stratified analyses for
men and women were conducted. If no effect modi-
fication was present, sex was added as a confounder
to the analyses. Adjustments for demographic vari-
ables (age, sex, education level, season of blood
collection) were made in Model 1; additional adjust-
ments for lifestyle/health confounders (smoking,
alcohol consumption, body mass index, number of
chronic diseases, physical activity, and cognitive func-
tioning) were made in Model 2.
Longitudinal Analyses
To study the course of depressive symptoms over
time, linear mixed-models analyses were conducted
with the 25(OH)D categories at baseline as determi-
nants, the CES-D scores after 3 years and 6 years as
outcome, and the baseline CES-D score as covariate.
These analyses included participants who had base-
line 25(OH)D and CES-D data and at least one follow-
up CES-D measurement. A random intercept was
added to the longitudinal CES-D variable to control
for dependency of individual measures over time. A
time-interaction term was added to the models to
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examine possible differences in the association between
3 and 6 years of follow-up.
To study whether 25(OH)D predicts the onset of clin-
ically relevant depressive symptoms over time, logistic
regression analyses were conducted in a subgroup of
participants without depressive symptoms at baseline
(CES-D < 16) and at least one follow-up measure-
ment. The outcome was defined as presence of clinically
relevant depressive symptoms (CES-D ≥ 16) in the 6-year
follow-up period. Models and effect modification pro-
cedures were similar to the cross-sectional analyses.
Finally, the possible mediating effect of physical per-
formance and functional limitations in the relationship
between 25(OH)D and depressive symptoms was ex-
amined in secondary analyses. To account for the
temporal, stepwise character of this hypothesized re-
lationship, two longitudinal mediation models were
fitted in which physical performance and functional
limitations after 3 years of follow-up were consid-
ered as the mediator variables. Using structural
equation modeling, the effect of 25(OH)D on physi-
cal functioning and the effect of physical functioning
on depressive symptoms (adjusted for 25(OH)D) were
simultaneously modeled. Mediation was examined only
in analyses that showed a statistically significant rela-
tionship between 25(OH)D and depressive symptoms.
With these mediation analyses, the total effect of
25(OH)D on depressive symptoms was separated into
direct and indirect effects. The direct effect repre-
sents the effect of 25(OH)D on depressive symptoms,
adjusted for physical functioning, whereas the indi-
rect effect represents the multiplied effects of 25(OH)D
on physical functioning and physical functioning on
depressive symptoms, adjusted for 25(OH)D. This in-
direct effect can be seen as the mediating effect of
physical functioning in the association of 25(OH)D with
depressive symptoms.32 Because of the usually skewed
distribution of indirect effects, we used 95% Monte
Carlo simulated confidence intervals (20,000
replications).33 The mediation analyses were per-
formed separately for physical performance and
functional limitations and were conducted in the ad-
justed models (Model 2).
Pooled Analyses
In additional secondary analyses, both cohorts were
pooled to increase the n and to investigate the
consistency of the findings. Because the cohorts used
different 25(OH)D assays, the 25(OH)D values of the
older cohort (Nichols assay) were calibrated towards
the values of the younger-old cohort (Diasorin assay),
using the formula Diasorin = 3.7778 + 0.8889 × Nichols.28
The cross-sectional and longitudinal regression anal-
yses were repeated in the pooled dataset, with cohort
as additional confounder.
RESULTS
Of 1,320 participants with a 25(OH)D measure-
ment in the older cohort, 38 participants were excluded
because of missing CES-D scores, leaving 1,282 par-
ticipants available for analysis. In this cohort, 217
participants (16.9%) had vitamin D deficiency
(25(OH)D < 30 nmol/L) and 400 participants (31.2%)
had insufficient 25(OH)D concentrations (30–50 nmol/
L). Clinically relevant depressive symptoms (CES-
D ≥ 16) were present in 193 participants (15.1%) at
baseline, in 202 of 1,071 participants (18.9%) at 3 years
and in 169 of 853 participants (19.8%) at 6 years of
follow-up. Non-response analyses comparing ana-
lyzed participants (n = 1282) with initially eligible
participants who were excluded from the cross-sectional
analyses (n = 227) showed that non-respondents were
older (U = 104,475.5, p < 0.001), less educated
(U = 130,516.0, p = 0.02), smoked more (χ2(2) = 8.9,
p = 0.01), drank less alcohol (U = 121,669.5, p < 0.001),
had more depressive symptoms (U = 96,413.0, p = 0.01),
were less physically active (U = 74,118.0, p < 0.001), had
worse cognitive functioning (U = 95,058.0, p < 0.001)
and physical performance (U = 72,670.5, p < 0.001), and
more functional limitations (U = 87,667.5, p ≤ 0.001),
compared with included participants. Non-response
analyses comparing participants who were excluded
from the longitudinal analyses (n = 207) with in-
cluded participants (n = 1075) showed similar results
as above. Furthermore, excluded participants were
more often male (χ2(1) = 34.6, p < 0.001) and had more
chronic diseases (U = 538,854.0, p = 0.01).
Of the 739 participants with a 25(OH)D measure-
ment in the younger-old cohort, two participants were
excluded from analysis for very high 25(OH)D con-
centration (182 nmol/L) or a missing CES-D score. Of
the resulting 737 participants, 56 participants had
vitamin D deficiency (7.6%) and 243 participants
had insufficient vitamin D status (33.0%). Clinically
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relevant depressive symptoms were present in 100 par-
ticipants (13.6%) at baseline, in 95 of 703 participants
(13.5%) after 3 years, and in 69 of 648 participants
(10.6%) after 6 years. Cross-sectional non-response anal-
yses in this cohort revealed that non-respondents
(N = 182) smoked more (χ2(2) = 14, 5; p = 0.001) com-
pared with included participants (N = 737).
Longitudinal non-response analyses showed that ex-
cluded participants (N = 33) had more depressive
symptoms (U = 39,562.0, p = 0.04), were more often
smokers (χ2(2) = 11, 3; p = 0.004), and had more func-
tional limitations (U = 33,340.0, p < 0.001) compared
with included participants (N = 704). Table 1 dis-
plays baseline characteristics of both cohorts.
Cross-Sectional Analyses
Table 2 presents the results of the baseline regres-
sion analyses. Sex was not an effect modifier in either
cohorts (cohort 1: t(1274) = −1.08 to −1.64, p = 0.10 to 0.28;
cohort 2: t(729) = −0.48 to −1.17, p = 0.24 to 0.63). In the
older cohort, participants with 25(OH)D less than
50 nmol/L had significantly more depressive symp-
toms compared with participants with 25(OH)D greater
than 75 nmol/L (<30 nmol/L: ratio = 1.25, 95% CI: 1.0–
1.5; 30–50 nmol/L: ratio = 1.17, 95% CI: 1.0–1.4). This
association was attenuated after adjustment for
lifestyle/health variables, however. Similarly, in the
younger-old cohort, no statistically significant cross-
sectional relationship between 25(OH)D and depressive
symptoms was seen in the adjusted model.
Longitudinal Analyses
In the older cohort, the interaction of sex with the third
25(OH)D dummy had a p value of 0.052 (t(1011) = 1.95).
As this value was very close to our preset 0.05 cutoff,
we decided to stratify the mixed-models analyses for
men and women, so we would not miss any potential-
ly relevant effects (Table 3). No significant associations
were observed in men, whereas women in baseline
25(OH)D categories below 75 nmol/L experienced more
depressive symptoms after 3 and 6 years compared with
women with 25(OH)D of greater than 75 nmol/L (ad-
justed model: < 30 nmol/L: ratio = 1.23, 95% CI: 1.02–
1.49; 30–50 nmol/L: ratio = 1.17, 95% CI: 1.00–1.37;
50–75 nmol/L: ratio = 1.24, 95% CI: 1.06–1.45). Corre-
sponding to these ratios, participants with 25(OH)D
concentrations below 30 nmol/L had a 23% higher
CES-D score over 6 years than persons with 25(OH)D
greater than 75 nmol/L. Similarly, participants with
25(OH)D concentrations of 30–50 nmol/L had a 17%
higher CES-D score over 6 years, and persons with
25(OH)D concentrations of 50–75 nmol/L had a 24%
higher CES-D score over 6 years compared with persons
with 25(OH)D levels greater than 75 nmol/L. It should
be noted that the overall test of the 25(OH)D catego-
ries for the adjusted model had a p value of 0.051
(F(3,553) = 2.60), but we still interpreted the associations
of the separate dummy variables as this value was so
close to the cutoff. This slightly higher p value was
caused by the association of the second dummy (30–
50 nmol/L) being less strong than the other two
dummies.
In the younger-old cohort, sex was not an effect mod-
ifier (t(686 to 691) = −0.53 to 0.25), p = 0.60 to 0.89). After
adjustment for lifestyle/health confounders, a signif-
icant relationship between baseline 25(OH)D and
depressive symptoms over time was no longer ob-
served (Table 3).
Time interaction terms were not significant in either
cohort (cohort 1: t(941 to 1010) = −0.85 to 0.65), p = 0.40 to
0.85; cohort 2: t(670 to 673) = −0.30 to 0.49), p = 0.63 to 0.77),
indicating that the effect of 25(OH)D on the course of
depressive symptoms did not differ between 3 and 6
years of follow-up.
In the logistic regression analysis of the older cohort,
sex was an effect modifier for the first and third
25(OH)D dummy (Wald(1) = 3.96, p = 0.047 and
Wald(1) = 6.83, p = 0.009, respectively). Hence, the anal-
yses were stratified for men and women. In the stratified
analyses, however, the overall tests for the association
of the 25(OH)D dummies with the onset of depres-
sive symptoms were not statistically significant for both
men and women (Wald(3) = 5.59, p = 0.13 and
Wald(3) = 4.78, p = 0.19, respectively), so analyses for the
separate 25(OH)D dummy variables were not per-
formed. Because of the small number of cases in the
stratified analyses, however, the reliability of these results
is uncertain. Similarly, in the younger-old cohort, no as-
sociations between 25(OH)D and the onset of depressive
symptoms were observed (Wald(3) = 0.57, p = 0.90).
Mediation of Physical Functioning
The mediation analyses for physical performance and
functional limitations were performed for the longi-
tudinal mixed-models analysis of the older women, as
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TABLE 1. Baseline Characteristics of the Two LASA Cohorts
Older Cohort (N = 1282) Younger-old Cohort (N = 737)
Serum 25(OH)D <30 nmol/L 30–50 nmol/L 50–75 nmol/L >75 nmol/L <30 nmol/L 30–50 nmol/L 50–75 nmol/L >75 nmol/L
(N = 217) (N = 400) (N = 434) (N = 231) (N = 56) (N = 243) (N = 310) (N = 128)
Depressive symptoms
CES-D score 9 [4–15] 7 [3–13] 5 [2–10] 4 [2–9] 10 [3–16] 6 [3–12] 5 [2–10] 6 [2–9]
CES-D ≥ 16 46 (21.2) 70 (17.5) 52 (12.0) 25 (10.8) 15 (26.8) 38 (15.6) 32 (10.3) 15 (11.7)
Women 135 (62.2) 240 (60.0) 201 (46.3) 83 (35.9) 28 (50.0) 135 (55.6) 158 (51.0) 78 (60.9)
Age, years 80.9 76.3 72.8 70.7 61.7 59.7 60.4 59.5
[75.5–84.5] [70.9–82.1] [68.8–78.5] [67.6–75.8] [58.0–63.2] [56.9–62.6] [57.5–62.6] [56.6–62.0]
Education, years 9 [6–11] 9 [6–11] 9 [6–11] 9 [6–11] 11 [7–15] 10 [9–12] 10 [9–11] 10 [9–11]
Season of blood collection
Winter 147 (67.7) 226 (56.8) 215 (49.7) 108 (46.8) 42 (75.0) 182 (74.9) 213 (68.7) 86 (67.2)
Summer 70 (32.3) 172 (43.2) 218 (50.3) 123 (53.2) 14 (25.0) 61 (25.1) 97 (31.3) 42 (32.8)
Smoking
Current 45 (20.7) 75 (18.8) 68 (15.7) 42 (18.2) 22 (39.3) 85 (35.0) 72 (23.2) 23 (18.0)
Former 75 (34.6) 167 (41.8) 231 (53.2) 121 (52.4) 21 (37.5) 108 (44.4) 161 (51.9) 67 (52.3)
Never 97 (44.7) 158 (39.5) 135 (31.1) 68 (29.4) 13 (23.2) 50 (20.6) 77 (24.8) 38 (29.7)
Alcohol consumption (g/
wk)
10 [0–70] 20 [0–70] 30 [5–120] 60 [10–210] 60 [5–210] 70 [20–200] 70 [30–210] 70 [45–210]
Body mass index (kg/m2) 26.8 27.3 26.5 25.6 26.5 27.6 26.6 26.4
[23.5–29.6] [24.7–30.0] [24.3–29.2] [23.4–28.2] [24.1–29.1] [24.5–30.3] [24.2–29.1] [24.6–29.0]
Number of chronic diseases 2 [1–3] 2 [1–3] 2 [1–2] 1 [1–2] 2 [1–3] 1 [0–2] 1 [0–2] 1 [0–2]
Cognitive functioning
(MMSE)
27 [24–28] 28 [26–29] 28 [26–29] 28 [27–29] 28 [26–29] 28 [27–29] 28 [27–29] 28 [27–29]
Physical activity (min/day) 21.4 38.6 56.8 61.5 48.0 66.4 72.9 62.9
[5.4–54.3] [15.0–65.4] [30.0–99.6] [28.8–102.1] [16.4–86.6] [35.4–109.3] [42.5–129.5] [37.9–110.0]
Physical performance a 6 [2–8] 7 [5–9] 9 [7–10] 9 [8–11] 6 [4–7] 6 [5–7] 6 [5–7] 6 [5–8]
Functional limitations 2 [0–4] 1 [0–3] 0 [0–2] 0 [0–1] 0 [0–2] 0 [0–1] 0 [0–0] 0 [0–1]
Notes: Values are displayed as N (%) for categorical variables or as median [interquartile range] for skewed continuous variables. 25(OH)D: 25-hydroxyvitamin D; CES-D: Center
for Epidemiological Studies Depression Scale; MMSE: Mini-Mental State Examination.


























TABLE 2. Cross-sectional Associations Between 25(OH)D and Depressive Symptoms in the Two LASA Cohorts
Older Cohort Younger-old Cohort
Model 1 Model 2 Model 1 Model 2
F (df1, df2) p Ratioa (SE) t (df) p F (df1, df2) p F (df1, df2) p Ratioa (SE) t (df) p F (df1, df2) p
Overall test of 25(OH)D
categoriesb
3.91 (3, 1270) 0.009 2.16 (3, 1238) 0.091 3.40 (3, 729) 0.017 1.35 (3, 710) 0.26
<30 nmol/L 1.25 (1.10) 2.41 (1270) 0.016 1.38 (1.16) 2.21 (729) 0.028
30–50 nmol/L 1.17 (1.08) 1.99 (1270) 0.047 1.20 (1.10) 1.87 (729) .0062
50–75 nmol/L 0.99 (1.08) −0.10 (1270) 0.92 1.01 (1.10) 0.07 (729) 0.94
>75 nmol/L Ref Ref
Notes: Analyzed with multiple linear regression analysis. Model 1: adjusted for age, sex, education, and season. Model 2: additionally adjusted for smoking, alcohol use, body
mass index, chronic diseases, cognitive functioning, and physical activity. 25(OH)D: 25-hydroxyvitamin D; CES-D: Center for Epidemiological Studies Depression Scale.
aAs the outcome variable was ln(1 + CESD), Bs and SEs were transformed back to normal scale to obtain interpretable ratios.
bThe individual 25(OH)D categories were tested only if the overall test of the categories was statistically significant.
TABLE 3. Longitudinal Associations Between 25(OH)D and Depressive Symptoms in the Older LASA Cohort; Stratified for Sex. Longitudinal Associations Between
25(OH)D and Depressive Symptoms in the Younger-old LASA Cohort
A.
Women Men
Model 1 Model 2 Model 1 Model 2
F (df1, df2) p Ratioa (SE) t (df) p F (df1, df2) p Ratioa (SE) t (df) p F (df1, df2) p F (df1, df2) p
Overall test of 25(OH)D
categoriesb
3.35 (3, 567) 0.019 2.60 (3, 553) 0.051 0.77 (3, 480) 0.97 0.12 (3, 464) 0.95
<30 nmol/L 1.30 (1.10) 2.69 (569) 0.007 1.23 (1.10) 2.13 (553) 0.034
30–50 nmol/L 1.23 (1.08) 2.61 (545) 0.009 1.17 (1.08) 1.92 (532) 0.055
50–75 nmol/L 1.26 (1.08) 2.92 (544) 0.004 1.24 (1.08) 2.70 (530) 0.007
>75 nmol/L Ref Ref
B.
Model 1 Model 2
F (df1, df2) p Ratioa (SE) t (df) p F (df1, df2) p
Overall test of 25(OH)D categoriesb 3.62 (3, 686) 0.013 1.91 (3, 670) 0.13
<30 nmol/L 1.31 (1.12) 2.46 (687) 0.014
30–50 nmol/L 0.99 (1.07) −0.18 (688) 0.86
50–75 nmol/L 0.94 (1.07) −0.85 (689) 0.40
>75 nmol/L Ref
Notes: Analyzed with linear mixed-models analysis, with the CES-D score after 3 and 6 years as outcome and baseline CES-D as covariate. Model 1: adjusted for age, sex, edu-
cation, and season. Model 2: additionally adjusted for smoking, alcohol use, body mass index, chronic diseases, cognitive functioning, and physical activity. 25(OH)D: 25-
hydroxyvitamin D; CES-D: Center for Epidemiological Studies Depression Scale.
aAs the outcome variable was ln(1 + CESD), Bs and SEs were transformed back to normal scale to obtain interpretable ratios.








































this analysis was statistically significant (Table 4). The
indirect effect (mediation effect) of physical perfor-
mance was statistically significant for the 30–50 nmol/L
25(OH)D category, compared with the reference cat-
egory of greater than 75 nmol/L (ratio of indirect effect:
1.03, bootstrapped 95% CI: 1.0–1.1). The correspond-
ing percentage mediation of 20.6% suggests that
physical performance after 3 years partially mediates
the longitudinal association between 25(OH)D and de-
pressive symptoms. The indirect effects of the other
25(H)D categories of physical performance and the in-
direct effects of functional limitations were not
statistically significant, but the substantial mediation
percentages of the less than 30 and 30–50 nmol/L cat-
egories suggest that physical functioning may have a
modest mediating role in the relationship between
25(OH)D and depressive symptoms.
Pooled Analyses
The cross-sectional and longitudinal regression anal-
yses were repeated in the pooled data set. Cross-
sectionally, participants in 25(OH)D categories up to
50 nmol/L experienced significantly more depres-
sive symptoms than participants with 25(OH)D greater
than 75 nmol/L in the adjusted model (<30 nmol/L:
ratio = 1.20, 95% CI: 1.03–1.40; 30–50 nmol/L:
ratio = 1.16, 95% CI: 1.03–1.30; Supplemental Table S1).
Corresponding to these ratios, participants with
25(OH)D less than 30 nmol/L had a 20% higher CES-D
score than persons with 25(OH)D greater than
75 nmol/L. Similarly, participants with 25(OH)D con-
centrations of 30–50 nmol/L had a 16% higher CES-D
score compared with persons with 25(OH)D greater
than 75 nmol/L. The longitudinal pooled analyses re-
vealed no significant associations between 25(OH)D
and depressive symptoms in the adjusted models
(Supplemental Table S2). Because of multiple cohort
differences, these results should be interpreted with
caution.
Sensitivity Analysis
As an additional sensitivity analysis, we examined
whether the results would be different if we ex-
cluded participants who indicated that their physical
activity pattern (confounder, LAPAQ) of the previ-
ous weeks was not representative of the previous year.
We repeated the tests for interaction of sex and the
cross-sectional and longitudinal regression analyses
without these participants (−28.2% and −31.4% in the
older and younger-old cohort, respectively) and the
results were very similar to the original analyses and
the conclusions did not change (results not shown but
available from the author on request).
DISCUSSION
This study investigated the baseline and prospec-
tive 6-year association between 25(OH)D concentrations
and depressive symptoms in two large population-
based cohorts of older adults. Cross-sectionally, this
association was not significant after adjustment for con-
founders, although the longitudinal analyses revealed
a difference between men and women in the older
TABLE 4. Mediation Effects of Physical Functioning (After 3 Years) in the Longitudinal Association Between Baseline 25(OH)D
and Depressive Symptoms Over 6 Years in Women of the Older LASA Cohort
Physical Performance Functional Limitations
Serum 25(OH)D Indirect Effect a 95% CI b % Mediationc Indirect Effecta 95% CIb % Mediationc
<30 nmol/L 1.03 0.99–1.07 12.4 1.04 0.99–1.09 16.7
30–50 nmol/L 1.03* 1.00–1.07 20.6 1.02 0.99–1.06 13.3
50–75 nmol/L 1.01 0.98–1.04 3.3 1.02 0.98–1.05 7.4
>75 nmol/L Ref Ref
Notes: As the outcome variable was ln(1 + CESD), the Bs and confidence intervals of the indirect effects were transformed back to normal
scale to obtain interpretable ratios. Mediation analyses were performed in the adjusted Model 2. 25(OH)D: 25-hydroxyvitamin D; CI: con-
fidence interval.
aThe indirect effect is the mediating effect of physical functioning on the association between 25(OH)D and depressive symptoms. It rep-
resents the multiplied effects of 25(OH)D on physical functioning and physical functioning on depressive symptoms, adjusted for 25(OH)D.
bBootstrapped confidence intervals with Monte Carlo simulation.
cPercentage mediation calculated by (indirect effect / total effect) × 100. Total effects are displayed in Table 3.
*Statistically significant indirect effect using the bootstrapped confidence interval.
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cohort (≥65 years at baseline): Women with 25(OH)D
concentrations <75 nmol/L at baseline experienced 17%
to 24% more depressive symptoms in the following
6 years than women with 25(OH)D > 75 nmol/L. Low
physical performance partially mediated this relation-
ship. No such associations were observed in men or
in the younger-old cohort (55–65 years old at base-
line). According to Geerlings et al., a change of 5 points
in the CES-D score can be regarded as a meaningful
change in depressive symptoms.34 Hence, it depends
on the initial CES-D score whether change in 25(OH)D
status is associated with a meaningful change in de-
pressive symptoms over 6 years. Higher initial CES-D
scores are associated with more relevant change.
The observed differences between the two cohorts
could be explained by the better general health status
of the younger-old cohort. These participants had higher
25(OH)D concentrations, better physical functioning,
fewer chronic diseases, and were physically more active
compared with the older cohort. This may have enabled
the younger persons to better withstand negative effects
of low 25(OH)D on mood. On the other hand, the
smaller sample size of the younger-old cohort may have
limited the power of our analyses.
To increase power and to investigate the consisten-
cy of the results, both cohorts were pooled in secondary
analyses. Cross-sectionally, these analyses demon-
strated significantly more depressive symptoms in
persons with lower 25(OH)D concentrations (up to
20%), confirming the consistency of the associations
in both cohorts. In the longitudinal pooled analyses,
however, the associations were not statistically signif-
icant. By comparing the longitudinal analyses of the
separate and pooled cohorts, the associations of the sep-
arate cohorts seemed to cancel each other out in the
pooled analyses, especially in the 30–50 and 50–
75 nmol/L categories (data not shown but available
from author on request). This may be explained by con-
siderable cohort differences regarding health status and
assessment periods. Because of cohort differences, the
results of the pooled analyses should be interpreted
with caution.
In the older cohort, a longitudinal association
between baseline 25(OH)D and the course of depres-
sive symptoms was observed in women only. This sex
difference could be attributable to the generally lower
25(OH)D concentrations in women compared with men
(25(OH)D < 50 nmol/L in 56.9% of women and 38.9%
of men). Milaneschi et al. found a similar sex differ-
ence in the InCHIANTI study.6 In contrast, no
interaction with sex was observed in the Health ABC
study.8
We hypothesized that low vitamin D status would
reduce physical functioning, which in turn would in-
crease depressive symptoms.14,15,18–20 Indeed, we
observed partial mediation of the association of
25(OH)D with depressive symptoms by physical per-
formance in secondary analyses. This provides evidence
for a potential mediating role of physical functioning
in the relationship between low 25(OH)D and increas-
ing depressive symptoms. To the best of our
knowledge, this explanatory role has not previously
been investigated prospectively. At most, these vari-
ables were treated as confounders in former studies.6–9,35
The influence of physical functioning may in fact be
an important reason why we did not observe signif-
icant associations in men and in the younger-old
participants. Men in the older cohort had better phys-
ical performance than women (U = 174,121.0, p < 0.001).
Similarly, participants in the younger-old cohort gen-
erally had higher physical function scores compared
with the older cohort (see Table 1). It can be specu-
lated that having adequate physical functioning may
act as a “buffer” to safeguard older persons from the
negative impact of low 25(OH)D on their mood. It
should be noted that this mediating role of physical
functioning is still exploratory and should be con-
firmed by other studies.
Hoogendijk et al. partly used the same data as the
present study and did find a significant cross-sectional
association between depression status and 25(OH)D
concentrations.2 This disparity can be explained by their
use of different confounders and different
operationalization of depression. Hoogendijk et al. cat-
egorized depression status into no depression (CES-
D < 16), minor depression (CES-D ≥ 16) and major
depressive disorder (MDD) (diagnosis after psychiat-
ric interview) and analyzed it as determinant instead
of an outcome. We chose not to use the MDD vari-
able as outcome, because the number of participants
with MDD is very limited within the LASA study,
which would substantially reduce the power of our
analyses.
The present study combines several strengths. The
use of data from two large, population-based, inde-
pendent cohorts with a long follow-up increases the
value and generalizability of our results. In addition,
we studied the influence of 25(OH)D on the severity,
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course, and onset of depressive symptoms using both
cross-sectional and longitudinal analysis techniques,
adjusted for relevant confounders. By studying
25(OH)D at baseline, physical functioning after 3 years,
and depressive symptoms over 6 years, we explored
the potential mediating role of physical functioning lon-
gitudinally. This method takes into account the temporal
character of the underlying mechanism. To the best of
our knowledge, this is the first study that explored
physical functioning as a possible mediating factor in
the relationship between vitamin D status and depres-
sive symptoms.
This study also has some limitations. Serum 25(OH)D
was only measured at baseline, although it was shown
that 25(OH)D concentrations are relatively stable over
time.28,36 Furthermore, as depressive symptoms were
measured only once every 3 years, we did not have
information about intermediate time points. Because
of the fluctuating nature of depression, we may have
missed episodes of depressive symptoms. Unfortu-
nately, some potential confounders were not measured
in the LASA measurement cycles that we used. Because
of this, we were unable to adjust for variables such as
diet and vitamin D supplement use, possibly result-
ing in residual confounding. Furthermore, over 99%
of LASA participants are Caucasian,28 which may have
limited the generalizability of our findings to other
ethnicities, as evidence suggests that polymorphisms
of the vitamin D binding protein and hence
bioavailability of vitamin D may differ between
ethnicities37 (but see Nielson et al.38). The non-response
analyses showed that included participants were
healthier than excluded persons, which may limit
generalizability. In addition, the physical activity
measure (LAPAQ) only provides information about ac-
tivities in the previous 2 weeks, and no information
about the longer-term habitual activity pattern of the
participants. Therefore, we conducted a sensitivity anal-
ysis without participants who indicated that their
activities were not representative for the previous year.
Results of these analyses were similar to the regular
analyses. Although this suggests that lack of informa-
tion on past-year physical activity does not influence
the conclusions, it cannot be ruled out that longer-
term habitual physical activity may still be a potential
confounding factor.
It should also be noted that we decided to inter-
pret the associations of the separate 25(OH)D dummy
variables for the women of the older cohort, although
the test for the overall effect had a p value of 0.051,
which was just above the cutoff of 0.05. This p value
was slightly higher because the association of the second
dummy (30–50 nmol/L) was less strong compared with
the other two dummies. In this case, the potential clin-
ical relevance of the findings made us decide to
interpret the separate dummy associations after all.
Replication of our findings by future research is there-
fore especially important in this case. Finally, cohort
differences, such as different time periods and 25(OH)D
assays, may have compromised the comparability of
the two cohorts.
In conclusion, this study showed that older women
with 25(OH)D concentrations below 75 nmol/L at
baseline experienced 17% to 24% more depressive
symptoms over 6 years compared with women with
25(OH)D concentrations greater than 75 nmol/L. This
relationship may be partially explained by reduced
physical functioning. To the best of our knowledge, this
longitudinal mediating role of physical functioning has
not been studied before. Our results suggest that having
25(OH)D concentrations greater than 75 nmol/L and
adequate physical functioning is especially impor-
tant for the mental health of older women. Randomized
controlled trials investigating both vitamin D supple-
mentation and behavioral interventions to improve
physical functioning should examine the causality of
these associations further, which may aid treatment or
prevention strategies for depression.
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